Coultreon Biopharma raised $125 million in Series A financing to advance its immunology pipeline.
- Amount
- $125M
- Stage
- Series A
- Announced
- 28 April 2026
- Leads
- Sofinnova Investments, Forbion, Novo Holdings
- Other investors
- Galapagos, Regeneron Ventures, Balyasny Asset Management, Luma Group, Samsara BioCapital, Longwood Fund, Finchley Healthcare Ventures
- Use of funds
- Advancing lead immunology program COL-5671 into psoriasis and ulcerative colitis Phase 2 trials
- Checked
- Amount and date checked against the press source